Interleukin-2 treatment of tumor patients can expand regulatory T cells

Augmented numbers of regulatory T cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory T cells, wh...

Descripción completa

Detalles Bibliográficos
Autor principal: Beyer, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494638/
https://www.ncbi.nlm.nih.gov/pubmed/23170272
http://dx.doi.org/10.4161/onci.20639
_version_ 1782249420476121088
author Beyer, Marc
author_facet Beyer, Marc
author_sort Beyer, Marc
collection PubMed
description Augmented numbers of regulatory T cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory T cells, which aggravates immunosuppression.
format Online
Article
Text
id pubmed-3494638
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34946382012-11-20 Interleukin-2 treatment of tumor patients can expand regulatory T cells Beyer, Marc Oncoimmunology Author's View Augmented numbers of regulatory T cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory T cells, which aggravates immunosuppression. Landes Bioscience 2012-10-01 /pmc/articles/PMC3494638/ /pubmed/23170272 http://dx.doi.org/10.4161/onci.20639 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Beyer, Marc
Interleukin-2 treatment of tumor patients can expand regulatory T cells
title Interleukin-2 treatment of tumor patients can expand regulatory T cells
title_full Interleukin-2 treatment of tumor patients can expand regulatory T cells
title_fullStr Interleukin-2 treatment of tumor patients can expand regulatory T cells
title_full_unstemmed Interleukin-2 treatment of tumor patients can expand regulatory T cells
title_short Interleukin-2 treatment of tumor patients can expand regulatory T cells
title_sort interleukin-2 treatment of tumor patients can expand regulatory t cells
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494638/
https://www.ncbi.nlm.nih.gov/pubmed/23170272
http://dx.doi.org/10.4161/onci.20639
work_keys_str_mv AT beyermarc interleukin2treatmentoftumorpatientscanexpandregulatorytcells

Ejemplares similares